An open-label, multicentre, single-arm, post-marketing trial to evaluate efficacy and safety and the impact of immunogenicity on efficacy, safety, and pharmacokinetics of spesolimab i.v. in treatment of patients with Generalized Pustular Psoriasis presenting with a recurrent flare following their initial GPP flare treatment with spesolimab i.v - NUHS Investigational Medicine Unit

Study Details	To evaluate efficacy and safety and the impact of immunogenicity on efficacy, safety, and pharmacokinetics of spesolimab i.v. in treatment of patients with Generalized Pustular Psoriasis presenting with a recurrent flare following their initial GPP flare treatment with spesolimab i.v
Protocol Number	BI1368-0120
Phase	IIIb/IV
Therapeutic Area	Dermatology
Subject Types	With Medical Condition
Indication	Generalized Pustular Psoriasis
Principal Investigator	Dr Chris Tan Lixian
Investigator Product / Device	Spesolimab
Sponsor	Boehringer Ingelheim Singapore Pte Ltd